


Novus Biologicals launches variety of products for studying Hypoxia

26 October 2015 | News | By BioSpectrum Bureau

Novus Biologicals launches variety of products for studying Hypoxia



Novus Biologicals has launched a range of products for studying various parameters associated with hypoxia.

Hypoxia is a pathological condition that arises due to diminished supply of oxygen to body tissues. Experimental evidence shows that hypoxia plays a major role in the pathology of various diseases including cancer, myocardial and cerebral ischemia, pulmonary hypertension, kidney disease etc. Various studies have shown that a number of proteins are affected during hypoxic conditions.

The new products include primary antibodies against various hypoxia targets such as HIF, EGLN etc., as well as hypoxia positive lysates, recombinant proteins and products for RNAi.

The wide range of products provided by Novus Biologicals allows user to study different aspects of hypoxia in a variety of applications such as immunohistochemistry, immunofluorescence, western blotting, ELISA and gene silencing.